For the year ending 2025-12-31, BCLI had -$95K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -10,307 |
| Depreciation | 199 |
| Stock-based compensation related to options granted to employees and directors | 1,520 |
| Change in operating lease liability, net | 87 |
| Decrease (increase) in prepaid expenses and other accounts receivable | 83 |
| Increase (decrease) in trade payables | 987 |
| Increase in accrued expense | 85 |
| Gain on change in fair value of warrants (note 7) | -179 |
| Increase (decrease) in employees related liability and accrued expenses | 716 |
| Total net cash used in operating activities | -6,975 |
| Proceeds from issuance of shares in at-the-market (atm) offering (note 8) | 4,347 |
| Proceeds from short-term loans (note 11) | 582 |
| Proceeds from warrants issuance (note 7) | 1,501 |
| Debt-for-equity swap | -450 |
| Total net cash provided by financing activities | 6,880 |
| Decrease in cash and cash equivalents | -95 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 371 |
| Cash, cash equivalents and restricted cash at end of the period | 276 |
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)